Rufinamide, Serum or Plasma
Optimize drug therapy and monitor patient adherence.
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain Red. Also acceptable: Lavender (K2 or K3EDTA), or Pink (K2EDTA).
Separate from cells ASAP or within 2 hours. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 2 weeks
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
|Therapeutic Range||5-30 µg/mL|
(values at dosages of 800-7200 mg/day)
|Toxic||Not well established|
Adverse effects may include somnolence, vomiting, headache and fatigue.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2003177||Rufinamide, Serum or Plasma||59323-6|
- banzel blood level
- rufinamide blood level